Understanding the Market | GIANT BIOGENE fell over 6% in the afternoon, and the new medical beauty products require a certain preparation time from approval to market promotion
GIANT BIOGENE fell over 6% in the afternoon, and as of the time of writing, it was down 4.51%, trading at HKD 39.8, with a transaction volume of HKD 513 million. In terms of news, GIANT BIOGENE previously announced that its "Recombinant Type I α1 Subtype Collagen Freeze-Dried Fiber" Class III medical device has been approved. This product is China's first recombinant Type I natural sequence collagen facial injection product, which has been officially approved through a joint review of device and drug assessments. Huatai Securities stated that considering the new medical beauty products require a certain preparation time from approval to market promotion, it maintains the company's net profit forecast for 2025-2027. CMB International published a report indicating that the online sales performance of KefuMei during the first phase of Double Eleven was relatively weak, estimating that KefuMei's online revenue in the second half of the year may decline by 10% year-on-year, dragging down KefuMei's overall online revenue growth rate to about 5%. However, KeliJin's annual online revenue is expected to achieve a high growth rate of about 40%. Offline business is expected to maintain steady growth. The firm expects the company's revenue growth forecast for 2025 to slow down to 12%
According to the Zhitong Finance APP, GIANT BIOGENE (02367) fell over 6% in the afternoon, and as of the time of publication, it was down 4.51%, trading at HKD 39.8, with a transaction volume of HKD 513 million.
In terms of news, GIANT BIOGENE previously announced that its "Recombinant Type I α1 Subtype Collagen Lyophilized Fiber" Class III medical device has been approved. This product is China's first recombinant Type I natural sequence collagen facial injection product, which has been officially approved through a joint review by the medical device and drug regulatory authorities. Huatai Securities stated that considering the time required for the new medical beauty product to be promoted after approval, it maintains its forecast for the company's net profit attributable to the parent for 2025-2027.
CMB International published a report indicating that the online sales performance of KefuMei during the first phase of the Double Eleven shopping festival was relatively weak. The firm estimates that KefuMei's online revenue in the second half of the year may decline by 10% year-on-year, dragging down KefuMei's overall online revenue growth rate for the year to about 5%. However, KeliJin's annual online revenue is expected to achieve a high growth rate of about 40%. Offline business is expected to maintain steady growth. The firm expects the company's revenue growth forecast for 2025 to slow down to 12%
